SOHM, Inc. Shares Progress On its Manufacturing Facility and Other Projects
CHINO HILLS, Calif. / — December 13, 2022 – SOHM, Inc. (Pink Sheets: SHMN) (the “Company”), a generic pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today some important updates.
Mr. Baron Night, CEO, stated that the manufacturing facility activities are going as planned. The fund for the facility is envisioned from its current, and future revenues as the Company has ongoing various purchase orders. The arrangement of the funds from its cash flow is planned and allocated in case the other funding is delayed for any reason. The Company anticipates using them to expand the state-of-the-art facility in a phased manner.
The Company’s funding actions are ongoing, as previously announced and appropriate due diligence for all its forthcoming pipeline projects, including the manufacturing facility, is in progress. Mr. Night, CEO, added.
As the world is going through economic challenges, supply chain issues, foreign exchange problems, and low demand for some of its prescription products in the USA market, the Company’s revenues and growth have also been affected. As a result, we are also impacted; however, due to our timely strategic actions, and collaborations, we have been able to sustain our stability, growth, and expansions, Mr. Baron Night, CEO, added.
Mr. Baron Night shared that SOHM can finish its targeted projects efficiently, as shared earlier. The Company plans to update its stakeholders about the new outlook after this significant development in the new year 2023.
Management continues its assurance that SOHM will achieve its target for higher revenue growth and has many more exciting updates in the year 2023.
About SOHM, Inc.
SOHM, Inc. is a growing generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” that tries to build continuous growth. SOHM manufacturing and marketing, targets the rapidly growing healthcare segments, such as nutraceuticals, cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America, with manufacturing alliances in India and strategic partnerships/alliances with U.S. manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and were introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To learn more about SOHM, Inc., visit www.SOHM.com.
Safe Harbor Statement:
This news release contains “forward-looking statements,” which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
For more information, please contact:
SOHM, Inc.
714-522-6700